Gefitinib Geftinat 250 mg
$111.00 – $315.00Price range: $111.00 through $315.00
|
Gefitinib Geftinat 250 mg
|
Variation | Price | Price / Unit | Quantity | Add To Cart |
|---|---|---|---|---|
| 30 Tablet/s | $111.00 | $3.7/ Piece | ||
| 60 Tablet/s | $216.00 | $3.6/ Piece | ||
| 90 Tablet/s | $315.00 | $3.5/ Piece | ||
Description
Gefitinib is a medication primarily used in the treatment of non-small cell lung cancer (NSCLC) that harbors specific genetic mutations known as epidermal growth factor receptor (EGFR) mutations. It belongs to a class of drugs known as tyrosine kinase inhibitors, which work by blocking the activity of specific proteins involved in cancer cell growth and spread. Gefitinib is specifically indicated for patients with locally advanced or metastatic NSCLC whose tumors have EGFR mutations. It is typically taken orally in tablet form.
| Active Ingredient (Generic Name): | Gefitinib |
| Manufacturer: |
Natco Pharma Ltd.
|
| Packaging: | 30 Tablets in Bottle |
| Strength: | 250 mg |
| Delivery Time: | 6 To 15 days |
| SKU: | Gefitinib Geftinat 250 mg |
Additional information
| Quantity Value | 30 Tablet/s, 60 Tablet/s, 90 Tablet/s |
|---|
Be the first to review “Gefitinib Geftinat 250 mg” Cancel reply
You must be logged in to post a review.
Related products
-

Regorafenib 40 mg
0 out of 5$216.00 – $613.00Price range: $216.00 through $613.00 Select options This product has multiple variants. The options may be chosen on the product page -

Anastrozole 1 mg
0 out of 5$75.00 – $510.00Price range: $75.00 through $510.00 Select options This product has multiple variants. The options may be chosen on the product page -

Lenalidomide 10 mg
0 out of 5$150.00 – $428.00Price range: $150.00 through $428.00 Select options This product has multiple variants. The options may be chosen on the product page -

Lenalidomide 25 mg
0 out of 5$300.00 – $878.00Price range: $300.00 through $878.00 Select options This product has multiple variants. The options may be chosen on the product page

Reviews
There are no reviews yet.